Pfizer's Pain Pipeline No Sore Spot: Firm Pursues Novel Targets, New Markets
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer's investment in pain R&D is aimed at capturing two of the most significant advantages in the pharmaceutical industry: unmet medical need and innovative drug targets. With a track record in the field and over 80 percent of its pain pipeline hitting novel targets, Pfizer should be well-situated to capitalize on that opportunity.